




The relative strengths and weaknesses of Lixte Biotechnology Holdings INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Lixte Biotechnology Holdings INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 113% points. The greatest weakness of Lixte Biotechnology Holdings INC is the variable Net Income, reducing the Economic Capital Ratio by 78% points.

The company's Economic Capital Ratio, given in the ranking table, is 279%, being 34% points above the market average of 245%.

Input Variable	Value in 1000 USD
Assets, Current	5,560
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	395
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	2,423
Other Liabilities	0
Other Net Income	7.8
Other Revenues	0
Property and Equipment	0
Research and Development	1,349
Selling, General and Administrative Expense	2,548

Output Variable	Value in 1000 USD
Assets	5,560
Liabilities	395
Expenses	6,320
Revenues	0
Stockholders Equity	5,165
Net Income	-6,313
Comprehensive Net Income	-6,313
BaseVar	6,141
ECR before LimitedLiability	166%
Economic Capital Ratio	279%